Index · 2 ranked
Funds Tracking the broad equity market listed and domiciled in the U.S. The
Ranked by expense ratio, lowest first.
Data as of May 31, 2026 ·How this data is built
As of May 31, 2026, FundVersus ranks 2 funds tracking the broad equity market listed and domiciled in the U.S. The by expense ratio. The lowest is Biotechnology Ultrasector Profund Investor Class (BIPIX) at 1.52%. The median is 2.02%; weighted by assets, 2.02%.
Facts from SEC filings. Not investment advice.
The ranking
Only the stated measure sets the order. Expense ratios from prospectuses; net assets and returns from Form N-PORT.
| # | Fund | Expense ratio | Net assets | 1-year return | |
|---|---|---|---|---|---|
| 1 | Biotechnology Ultrasector Profund Investor ClassBIPIX · Mutual fund · Leveraged and Inverse | 1.52% | $183M | +88.15% | |
| 2 | Biotechnology Ultrasector Profund Service ClassBIPSX · Mutual fund · Leveraged and Inverse | 2.52% | $183M | +86.24% |
Questions
How is this list ranked?
Ranked by expense ratio, lowest first. It includes funds tracking the broad equity market listed and domiciled in the U.S. The with a current SEC filing and enough data for a FundVersus page. The ranking uses one stated measure and is not a recommendation.
Which has the lowest expense ratio?
Biotechnology Ultrasector Profund Investor Class (BIPIX), at 1.52% as of May 31, 2026.
How much money is in these funds?
The 2 funds on this list reported $365M in combined net assets on their latest filings.